Shares of Glaukos Corporation (GKOS) plummeted 11.62% in Thursday's pre-market trading session following a series of price target cuts by prominent Wall Street analysts and a downgrade from Wells Fargo. The ophthalmic medical technology and pharmaceutical company faced significant downward revisions, signaling growing concerns about its near-term prospects.
JP Morgan delivered the most severe blow, slashing its price target for Glaukos from $160 to $100, a staggering 37.5% reduction. This was followed by Needham, which cut its target from $176 to $115, and Truist Securities, lowering its target from $140 to $135. Stifel and Mizuho also joined the bearish chorus, reducing their price targets to $115 from $140 and to $150 from $175, respectively.
Adding to the negative sentiment, Wells Fargo downgraded Glaukos to Equal Weight from Overweight, drastically reducing its price target to $86 from $160. The firm cited that the growth runway for iDose, one of Glaukos's key products, is already priced into the stock. This collective action by analysts suggests a significant reassessment of the company's future performance and growth potential, leading investors to reconsider their positions and triggering a substantial sell-off in pre-market trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.